New hope for black caribbean women with aggressive breast cancer: could a different chemo drug work better?

NCT ID NCT07528768

Not yet recruiting Disease control Sponsor: AntiCancer Research Jamaica Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two chemotherapy drugs—gemcitabine and paclitaxel—in Black Caribbean women with metastatic triple-negative breast cancer. The goal is to see if gemcitabine, usually used later, works better as a first treatment. 750 women from Jamaica, Trinidad, and Barbados will take part, with regular check-ups and scans to track results.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC TRIPLE-NEGATIVE BREAST CANCER TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

St. James Medical Complex

Port of Spain, Saint James, Trinidad and Tobago
The Queen Elizabeth Hospital

Bridgetown, Saint Michael, Barbados
The University of the West Indies, Mona

Mona, Kingston, Jamaica

More trials for these conditions

Other studies related to the condition(s) this trial covers.